Urologic oncologist; healthcare administration
New Haven, CT
Joined June 2014
- Tweets1.9K
- Following1.2K
- Followers1.4K
- Likes8.9K
Hypoprolenemia
Intraoperative adverse events occurred in 41 of 478 patients (8.6%) undergoing robot-assisted minimally invasive esophagectomy, and 92.7% were managed robotically without conversion. ovid.com/10.1097/SLA.0000000…
Patrick Kenney retweeted
Yale Urology is seeking a PGY-3 resident to join our program starting July 1, 2026. We offer exceptional surgical training, high-volume operative experience, all subspecialties, diverse practice settings, research opportunities, and career mentorship. 🧵1 of 2
Patrick Kenney retweeted
.@BraunMDPhD and colleagues tested a “live tumor fragment” lab assay/elive platform using biopsies to predict response to ICI. In a small validation (20 pts later treated with ICI) the Elephas score correctly flagged 82% of responders and 100% of non-responders, including 2 responders missed by standard biomarkers. Larger validation is ongoing. #ASCO26 @SmilowCancer @ASCO @OncoAlert
Patrick Kenney retweeted
.@BraunMDPhD & Dr. Zachary Yochum @YaleHemOnc at #ASCO26: Spatial multi-omics mapping of #kidney tumors showed aggressive rhabdoid/sarcomatoid regions are rich in immune cells, with T cells that appear both activated and exhausted. These findings may help explain why some high-risk tumors still respond to checkpoint immunotherapy. @ASCO @SmilowCancer @OncoAlert
Patrick Kenney retweeted
Thank you for featuring our work. Huge appreciation to all collaborators, patients and their families!
@DrChoueiri @YaleMed @kidneycan @OncoAlert @syudaikouhou @urol_jua
At #ASCO26, @kashimamdphd @BraunMDPhD share why some #kidneycancer tumors don’t respond to immunotherapy despite having plenty of T cells. Research found many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. Blocking TGF-β1 helped restore T cell activity, pointing to a potential new way to overcome resistance. @ASCO @SmilowCancer @OncoAlert
Patrick Kenney retweeted
At #ASCO26, @kashimamdphd @BraunMDPhD share why some #kidneycancer tumors don’t respond to immunotherapy despite having plenty of T cells. Research found many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. Blocking TGF-β1 helped restore T cell activity, pointing to a potential new way to overcome resistance. @ASCO @SmilowCancer @OncoAlert
Patrick Kenney retweeted
As many other oncologists will also attest, we were taught this was a dead end
It was, dogmatically, never going to work — kras was too much of a “greasy ball” to be targeted
And yet here we are, with truly meaningful survival curves👇
Inspiration on multiple levels #ASCO26
Patrick Kenney retweeted
We are hiring! We are specifically looking for a postgraduate associate - someone who has recently finished university and is ultimately looking to apply to medical school or graduate school.
It is a TWO YEAR clinical/translational position, where you will be interacting closely with patients, involved in translational clinical trials, and working hands on in the lab and with clinical databases.
The ideal candidate is a great communicator, organized, and enthusiastic about patient-oriented clinical and lab research. You will get dedicated mentoring not just on the science and clinic, but also on career/professional development as well.
We are looking for someone to start ASAP! More information here:
postdocs.yale.edu/posts/2026…
Please help to spread the word and RT!
@DrChoueiri @VanAllenLab @tompowles1 @YaleCancer @YaleMed @SmilowCancer @kidneycan @OncoAlert @OncLive @KidneyCancer @A_P_S_A @cure_today @yalepathology @Yale_Urology @DrYukselUrun @MarkDSiegel1 @OncBrothers @DrKarineTawagi
Ok
As long as we’re on the topic — masses shouldn’t be described in an imaging report as being “inseparable” from an adjacent organ. That means something different to surgeons!
🚨Radiology twitter:
STONE(S) in URETER:
My view is the word "nonobstructing" should never be used.
A ureteral stone may have no associated hydro because:
1. It truly is letting urine by
2. It's intermittently obstructing, and you happened to catch it after the upper tract decompressed
3. The patient is trying to die, septic, in shock, not making urine. 💀☠️
Words matter because the non urology care team sees the word "nonobstructing" as "not a problem" and may not consult urology.
Anyone disagree with this? Would love to see alternate perspectives.
If patients can’t complete the intervention it would stand to reason that the intervention does not work…
This quoted post is unavailable.
Patrick Kenney retweeted
Welcome to the new chair of Albany Medical Center Urology, Dr. Lara MacLachlan, who specializes in urogynecology and reconstructive pelvic surgery. albanymed.org/news/albany-me…
Patrick Kenney retweeted
YES!
Bursting with pride to see our 2013 residency alumna Dr. Lara MacLachlan @MacLachlanLara named CHAIR of @AlbanyMedUro !!
They could not have chosen a better leader.
#roots @SWIUorg @sufu @AmerUrological @AlbanyMed @LaheyUro
Patrick Kenney retweeted
State-of-the-art talk from Le @BraunMDPhD on anti tumor immunity in RCC @BrighamMedRes Medical grand round.
Walking us through the full arc of the field and investigations over the years:
1. Systemic therapy landscape overview —> ICIs have been transformative, but many patients still do not benefit.
2. Determinants of anti-tumor immunity, including PBRM1 and 9p21.3 deletions.
3. Progressive CD8 exhaustion with advancing disease, M2 like TAM programs, and CD8 TAM interaction signature linked to worse outcomes.
4. Exceptional responders and the weight of TLS and humoral immunity.
5. The future ==> personalized medicine with neoantigen vaccination.
@DanaFarber_GU @Yale @YaleMed @MGBResearchNews @MassGenBrigham
#RCC #Immunotherapy #CancerImmunology
Patrick Kenney retweeted
4/ Our very own @BraunMDPhD’s personalized neoantigen vaccine in high-risk ccRCC in @Nature (Work from #WuLab @DanaFarber who pioneered that technology). Hits driver mutations (VHL, PBRM1, BAP1, KDM5C, PIK3CA) & generates durable T-cell expansion and tumor recognition. 0/9 recurrences at ~40 months. Promising adjuvant therapy in RCC!
@DanaFarber @DanaFarber_GU @Yale
nature.com/articles/s41586-0…
Patrick Kenney retweeted
Sincere congratulations to my mentor, friend and partner @ejasonabel for winning the well deserved Andrew novick award. Outstanding surgeon, scientist, father who has taught me so much. #IKCSNA2025
Patrick Kenney retweeted
🌟Congratulations @sidichen @YaleCancer!
He is the KCA-@CancerResearch Clinic & Laboratory Integration Program (CLIP) Investigator to research how CAR-T cell therapy could be better used in solid tumors like #kidneycancer.
Patrick Kenney retweeted
🎉 Congratulations @ejasonabel who will receive the KCA's Andrew C. Novick Award at #IKCSNA25! This award recognizes excellence in #kidneycancer urology care.
Read more: kidneycancer.org/2025-ikcsna…
Patrick Kenney retweeted
✨ Our weekly Application Polishing Office Hours are TONIGHT! ✨
🗓 4–6 PM PT (7–9 PM EST)
With mentors:
👩🏾⚕️ Dr. @OlamideOlawo ( @Yale_Urology )
👩🏾⚕️ Dr. @FortingoKuna ( @VCUUrology )
📍 Calendar invite + Zoom link sent to members. Also shared in our GroupMe!
Patrick Kenney retweeted
Congratulations to @arihakimi who was chosen unanimously by the class of 2025 Urologic Oncology Fellows as Teacher of the Year. Well deserved! @MTDawidek @MariaPereMD @sunny_nal @therealUroJET @UroMuneeb
Patrick Kenney retweeted
Might a #kidneycancer #vaccine that prevents recurrence change the trajectory for patients with the disease? It’s possible, based on a recently published Yale study. Though the study is small and early stage, the results are very promising.
Read here: bit.ly/3G1YsDC
